stockrowMetagenomi Therapeutics, Inc.
Metagenomi Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $25.2 million, down 51.8% from fiscal 2024.
- Revenue
- −103.0%
- EPS
- −35.2%
- Free cash flow
- +7.98%
Quarter to June 2026, against a year earlier
Follow MGX
Alert me
Metagenomi Therapeutics, Inc. (MGX) EV/Sales
As of 6 November 2026, Metagenomi Therapeutics, Inc. (MGX) trades at a EV/Sales of −4.7×. Over the past ten years it has ranged from −4.7× (November 2026) to −0.9× (October 2025) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −2.8× | — |
| FY2024 | −1.9× | — |
| FY2023 | −4.6× | — |
| FY2022 | −4.6× | — |
| FY2021 | −4.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −3.4× | — |
| Mar 2026 | −2.7× | — |
| Dec 2025 | −2.8× | — |
| Sep 2025 | −2.1× | — |
| 10 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MGX Metagenomi Therapeutics, Inc. | −4.7× |
| ACET Adicet Bio, Inc. compare | −2.2× |
| ANVS Annovis Bio, Inc. compare | n/m |
| BCTX BRIACELL THERAP compare | n/m |
| PLRZ Polyrizon Ltd. compare | n/m |
| ALGS Aligos Therapeutics, Inc. compare | 0.4× |
| BYSI BeyondSpring Inc. compare | 15.4× |
| ABVC ABVC BioPharma, Inc. compare | 20.6× |
| EDSA Edesa Biotech, Inc. compare | 28.0× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)